Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,263 total articles
<p>SK Hynix is shifting from classic memory-cycle exposure toward a more contractual, infrastructure-like role in AI datacenters. We think the market will increasingly value predictable supply agreements for HBM and specialized DRAM as comparable to other forms of hardware infrastructure revenue. That re-rating provides an asymmetric trade opportun…
BrightSpire's commercial real estate loan book is beginning to show the earnings power investors have been waiting for. The stock yields north of 12% and trades below book, while recent cash flow and falling short interest suggest a window for a mid-term long trade. This idea lays out an entry at $4.95, a stop at $4.30 and a target of $6.15 over a …
Vertiv's Q2 revenue miss has rattled the stock, but the company's core exposure to AI data center power and cooling plus strong cash generation make this a compelling trade. We upgrade to long and lay out a clear entry at $240.20, a $360 target and a $210 stop for a long-term (180 trading days) tactical position.
MongoDB's stock has pulled back from its 52-week highs, but the business metrics that matter - Atlas growth, positive free cash flow of $591M and improving technicals - point to a mid-term buying opportunity. This trade idea outlines an entry at $328.00, a $400 target and a $300 stop, with a primary horizon of 45 trading days and clear catalysts an…
W.P. Carey offers a roughly 5% yield, built-in rent escalators across a 1,700+ net-lease portfolio, and free cash flow that still covers the dividend. The stock trades near mid-range of its 52-week band with reasonable valuation (P/B ~2, P/E ~25.6) and an enterprise value of about $25.6B. We recommend a tactical long: entry $73.56, target $78.00, s…
Telix (TLX) is executing across commercial rollouts and multiple late-stage programs while stitching together a platform approach to radiopharmaceuticals. With Q2 revenue of $247M, Precision Medicine sales of $202M, and FY2026 guidance to exceed $1B, the business is shifting from single-product commercial risk to a scalable radiopharma operating sy…
Microsoft is benefitting from accelerating AI-driven demand in Azure, strong free cash flow and a healthy balance sheet. I lay out an actionable long trade with entry, stop and target that balances momentum with valuation and explicit risk controls.
SoFi reported a breakout quarter of revenue and membership growth, and the numbers argue the company is finally monetizing its
T-Mobile's stock has been pushed lower by headline risk tied to SpaceX's Starlink momentum and investor confusion after Q2 volatility. Fundamentals remain solid: 9% service revenue growth, raised free cash flow guidance to $18.4-18.8B, healthy free cash flow of $18.4B, and an EV/EBITDA of 8.3. This trade idea lays out an actionable long trade with …
Fulcrum (FULC) is a speculative buy after the June discontinuation of pociredir and a subsequent strategic review. Market cap trades below the company's stated cash reserves, the pipeline retains clinical promise and the company has time to execute alternatives. This trade idea outlines entry, stop and targets for a mid-term swing position while fl…
Align Technology (ALGN) trades at a reasonable multiple vs. its growth profile and has positive operational signs — record Invisalign submissions and activist interest — but topline momentum remains tepid. This trade idea outlines a long entry on a pullback, clear risk controls, and what to watch over a 180-trading-day horizon.
Innate Pharma (IPHA) trades at roughly $168M market cap with multiple clinical-stage assets in oncology. The shares sit near $1.75 after pulling back from a $2.62 52-week high; average volumes are low and short interest has been meaningful. For traders willing to accept binary clinical and financing risk, a controlled long swing (mid term, 45 tradi…
Penguin Solutions reported a blowout Q3 with 48% revenue growth to $479M and raised full-year guidance, signaling durable demand for its memory and AI infrastructure products. Valuation is elevated but supported by accelerating gross margins and pricing power as memory supply tightness benefits vendors focused on AI workloads. We outline a mid-term…
SK hynix has been punished with a cascade of weak sentiment that looks priced for a worst-case memory depression. I upgrade to Buy: this is a tactical, data-driven play on improving DRAM/NAND fundamentals, inventory destocking ending, and an easily imaginable earnings rebound. Trade plan included with exact entry, stop and target for a mid-term swi…
Veeva's recent pullback after a solid Q1 print looks like an opportunity. The company reported EPS of $2.24 and revenue of $882.95M on 06/03/2026, raised FY2027 guidance, and sits on healthy cash flow. At the same time the stock trades at elevated multiples and investors have priced strong future growth. We rate VEEV a buy from $201.54 with a defin…
AeroVironment (AVAV) has been punished on program stops and litigation headlines, but balance-sheet resilience, a steady pipeline of counter-UAS and loitering munition contracts, and improving technicals suggest the bottom may be forming. This trade idea outlines a disciplined long with entry at current levels, a stop below the recent low, and a ta…
IonQ's headline metrics look frothy, but two questions - can the company sustain hyper-growth in commercial quantum services and does it have a cash runway to get there - have answers that justify a tactical long. Strong top-line momentum, a $3.0B cash war chest and improving technicals make this a high-risk, high-reward long idea with defined risk…
Eastman Chemical (EMN) reported the kind of operational resilience that matters for a cyclical specialty-chemicals name: solid free cash flow, a manageable balance sheet, and pricing power from regional feedstock tightness tied to Middle East supply disruptions. At a market cap just over $8.0B and EV/EBITDA near 9.2x, the stock looks reasonably val…
Synchrony Financial is cheap on P/E and P/B, returning capital aggressively via a $6.5B buyback that could retire roughly 25% of the company by market-cap terms. Credit metrics are improving and loan losses are trending down. This trade plan targets upside to $86 with a $70 stop, sized for a long-term (180 trading days) holding period.
Salesforce's AI products are scaling fast, with Agentforce ARR hitting $1.2B and a $1.6B federal contract validating product-market fit. Yet overall revenue growth and margin expansion haven't caught up to the hype. Valuation (roughly $148B market cap, ~18x earnings, EV/EBITDA ~12) leaves room for disappointment. I recommend a mid-term short with e…
Athabasca Oil is trading below its 52-week high but shows signs of an earnings- and cash-flow-driven rerating as thermal and light oil operations stabilize. The setup favors a controlled long: enter near $7.40, place a stop at $6.50, and target $11.00 over a 180-trading-day horizon, with clear catalysts and risk controls tied to commodity swings an…
Gatekeeper Systems appears to have moved from defensive restructuring into a growth-and-profit phase. Revenue momentum and improving margins set up a clean technical and fundamental entry. This trade targets a mid-term move with a strict stop and a longer-term stretch target if execution continues.
Mohawk's share price has been punished by cyclical weakness in residential construction and energy-driven input cost pressure. The business still generates healthy free cash flow ($709m), carries modest leverage (debt/equity 0.25) and trades at attractive multiples (P/B ~0.83, P/E ~17). This trade idea outlines a structured long with defined entry,…
Enterprise Products Partners (EPD) offers a 5.6%+ yield, predictable fee-based cash flow and attractive valuation metrics for income-minded traders. This trade idea targets a mid-term entry around $38.20 with a $42.00 target over ~45 trading days and a $36.00 stop. The setup balances current income (quarterly distribution) with capital appreciation…
Hims & Hers (HIMS) combines a direct-to-consumer telehealth platform, recurring prescription flows and a growing international footprint. After a volatile 2026 with margin compression, debt-funded M&A and headline risk, the stock trades at roughly $6.26B market cap and a modest 2.4x price-to-sales. For disciplined traders, a long position with tigh…
